Fosamax and Osteonecrosis of the Jaw: Medical Literature on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Risk Awareness

The legacy context of general health and science information often serves as a broad foundation for public awareness, covering a wide range of medical topics without specific focus on occupational or environmental exposures. Within this framework, discussions of medication side effects, such as those associated with bisphosphonates like Fosamax, have traditionally been situated in clinical or patient-oriented settings. The recognized risk of osteonecrosis of the jaw (ONJ) in patients receiving high-dose or long-term bisphosphonate therapy has been documented primarily in the context of therapeutic use, particularly for osteoporosis or cancer-related bone conditions. This established knowledge base provides a starting point for considering how such risks might extend beyond the patient population. As we pivot from this general health heritage, it becomes relevant to examine whether similar exposure concerns arise in occupational environments. Workers in industries involving the manufacture, handling, or application of bisphosphonate compounds may encounter these substances through inhalation or dermal contact. The transition from a clinical to an occupational perspective requires careful consideration of exposure routes, durations, and concentrations that differ from therapeutic regimens. This shift in focus allows for an exploration of potential risks to workers, moving from a patient-centered understanding of drug safety to a broader occupational health concern.

Bridging Clinical and Occupational Perspectives on Fosamax Exposure

While the clinical use of Fosamax (alendronate) is well-documented for osteoporosis and Paget's disease, the potential for occupational exposure to bisphosphonates raises distinct questions. The transition from a patient-centered to an occupational health framework necessitates examining how workers might be exposed to Fosamax or similar compounds during manufacturing, handling, or application. Unlike therapeutic dosing, occupational exposure may involve lower concentrations over longer periods, or acute exposures via inhalation or skin contact. Understanding the mechanisms of Fosamax-induced ONJ is critical to assessing risk in any context. Fosamax is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suppression can impair normal bone remodeling and repair, particularly in the jawbone, which undergoes high turnover due to mechanical stress and dental procedures. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The reduced ability to remodel bone may lead to microdamage accumulation and compromised vascularity, predisposing the jaw to necrosis, especially after invasive dental procedures.

Medical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a recognized adverse effect of bisphosphonate therapy, including Fosamax. ONJ is characterized by exposed necrotic bone in the maxillofacial region, often associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation includes pain, swelling, infection, and non-healing extraction sockets. Diagnosis relies on clinical examination and imaging, with exposed bone persisting for more than eight weeks in the absence of prior radiation therapy. Known risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the UK Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). The timeline between exposure and harm varies; time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief after stopping, but a subset had recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Warning Adequacy

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ development, excluding other causes such as radiation therapy or metastatic disease, and considering known risk factors. The timeline of exposure, with onset ranging from days to months after starting the drug, and increased risk with longer duration, support a causal association. Recurrence upon rechallenge further strengthens this link. However, low absolute risk and the possibility of spontaneous ONJ complicate individual causation assessments. Regarding warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on Fosamax should have the drug discontinued and receive appropriate dental management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it used?

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence.

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed necrotic bone in the maxillofacial region, often associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax, like other bisphosphonates, suppresses bone turnover, which can impair normal remodeling and repair in the jawbone, predisposing it to necrosis, especially after invasive dental procedures.

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk increases with longer duration of bisphosphonate exposure.

How long does it take for ONJ to develop after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, but a subset may have recurrence if rechallenged with the same or another bisphosphonate.

What should I do if I develop symptoms of ONJ while taking Fosamax?

If you develop symptoms such as pain, swelling, infection, or non-healing extraction sockets, consult your healthcare provider immediately. Discontinuation of bisphosphonate treatment may reduce the risk for ONJ, and appropriate dental management should be initiated (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.